Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

In 2012, the American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD) published a position statement on the management of …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalizations
and death from heart failure (HF), but their effect on arrhythmia expression has been poorly …

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a
metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Aim To assess the comparative efficacy and safety of sodium‐glucose co‐transporter‐2
(SGLT2) inhibitors in adults with type 2 diabetes. Methods We electronically searched …

Diabetologia (2015) 58: 429–442 DOI 10.1007/s00125-014-3460-0 management of
hyperglycaemia in patients with type 2 diabetes [1, 2]. This was needed because of an …

Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2)
inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to …

Background The sodium‐glucose cotransporter 2 (SGLT 2) inhibitors are a class of oral
hypoglycemic agents. We undertake a systematic review and meta‐analysis of prospective …

Context: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2
diabetes mellitus (T2DM). Objective: The purpose of this study was to describe the effects of …